Chief Executive Officer – Dr. Fred Regnier
was the J.H. Law Distinguished Professor of Chemistry at Purdue University and then joined Novilytic as the Chief Executive Officer in 2013. He has co-authored 306 peer reviewed publications in the fields of chromatography, proteomics, and metabolomcs and holds 47 patents in analytical and diagnostic science. Dr. Regnier was the Chief Scientific Officer at PBIO for 3 years, directing an R&D staff of ~100. He has co-founded five companies including:
- PerSeptive Biosystems (PBIO) – which developed analytical and preparative tools and sold to Applied Biosystems
- BG Medicine (BGMD) – which makes diagnostic tests for heart failure
- Quadraspec – which made diagnostic products for the veterinary market, later sold to Antech
- Perfinity Bioscience – which specializes in protein sample preparation ahead of mass spectrometry analysis
- Novilytic – which simplifies the preparation of blood samples for analysis
Dr. Fred Regnier – CV
Chief Scientific Officer – Dr. Jiri Adamec is currently an Associate Professor at Department of Biochemistry at University of Nebraska – Lincoln. He also serves as a Director of Proteomics and Metabolomics Core Facilities at Redox Biology Center at UNL. He has co-authored more than 60 peer reviewed publications and serves as a reviewer of Science and journals. Many of his publications focus on proteomic and metabolomics approaches to Systems Biology. Dr. Adamec worked at the Bindley Bioscience Center at Purdue University and was member of their board prior to joining Novilytic.
Chief Operating Officer -Tim Woenker has spent over 30 years of his professional career as a manufacturer of in-vitro diagnostic medical devices, during which time he was involved with invention and development of NoviPlexTM technology. Tim designed and operates a manufacturing facility for the Noviplex cards that is compliant with the USFDA, cGMP and Quality Systems requirements for in-vitro medical devices, registered under ISO 13495 (2003) in accordance with EU Directive 98/79/EC for distribution within the European Union, and registered under Canadian Medical Devices Conformity Assessment System (CMDCAS).
Director Sales & Marketing – Dr. Tim Schlabach has a lengthy career in product management and business development forscientific instruments. He has published more than 30 peer reviewed publications and authored two patents. He opened a west coast demo center for Perseptive Biosystems which conducted product demonstrations of chromatography and mass spectrometry instruments. He has led the marketing efforts for amino acid analyzers, protein sequencers, capillary electrophoresis and mass spectrometers at major instrument companies including Varian, Applied Biosystems, Spectra Physics and Thermo. He was the senior product manager for Agilent’s successful entry into the competitive LC Triple Quad market.
Director of Analytics – Dr. Jinhee Kim was a member of the Bindley Bioscience Center at Purdue University and then took a position with the Proteomics Assessment for Cancer Center at Purdue University until joining Novilytic. She has extensive experience with the analysis of proteins and peptides by mass spectrometry and wide experience with software tools needed to identify proteins and their isoforms.
Financial Controller – Ed Woenker has held senior positions at Chematics in Marketing and Finance. He has many years of experience in the medical device industry and in managing dealer networks.
Dr. Mike Lee
is a founder of the Annual Symposium on Clinical and Pharmaceutical Solutions through Analysis (CPSA). These unique events, held in the US, China and Brazil, highlight industry-related applications and feature sessions promoting discussion on real-world experiences with the latest analytical technology and industry initiatives.
An editor with John Wiley & Sons, Dr. Lee is responsible for a book series on Pharmaceutical and Biotechnology: Practices, Applications and Methods. He co-edited a book on Dried Blood Spots: Applications and Techniques, published by Wiley.
Financial Conflict of Interest (FCOI) Policy